Researchers at the Salk Institute for Biological Studies have uncovered a protein that plays a role in active HIV replication, essentially acting as part of a switch to turn HIV-1, the most common type of HIV, from a dormant state to an active one.
Some Indian companies that had put off production of HIV/AIDS meds while they waited for the government to sign contracts are now having to seriously ramp up because of shortages of some meds, Reuters reports.
New technology has allowed researchers to view HIV proteins in action, zooming in on so-called spikes that help the virus bind to cells it infects. The research puts scientists one step closer to a vaccine that could effectively prevent transmission of HIV and halt the spread of AIDS, an international epidemic.
Swiss firm Mymetics is getting a boost from the Bill and Melinda Gates Foundation to conduct a key animal study for its HIV vaccine candidate at the Texas Biomedical Research Institute.
Gilead has been seeking FDA approval for HIV drugs Tybost and Vitekta for a while now, but the agency dealt the drugmaker a setback with Complete Response Letter last year. Now, 17 months later, the two have passed muster.
A new monkey study points to how a cancer treatment that the famous "Berlin patient" underwent may have resulted in HIV being eradicated in his body.
A new sheds light on three different factors that may have contributed to ridding HIV from the "Berlin patient."
The U.S. National Institutes of Health devoted $20 million to develop an HIV drug-delivering intravaginal ring. The design of a successful ring is a priority in HIV research, and the sustained release of drugs the ring offers could eventually play a crucial role in HIV prevention in the developing world.
Researchers have designed a novel suppository for HIV antiretroviral delivery using the seaweed extract carrageenan. Almost half of the antiretroviral drug tenofovir diffused out of the delivery mechanism within the first two hours in an in vitro study testing the product in water, vaginal simulant fluid and semen simulant fluid.
The discovery of a new HIV antibody highlights the need to create vaccines with trimeric delivery systems that resemble those found naturally, said Mark Connors, the research team's principal investigator and chief of the HIV-Specific Immunity Section.